HCKT333M overexpression did not affect the potency of either ibrutinib or acalabrutinib in the tested MCL cell lines (Fig. 2B, C), indicating that the growth effects of neither BTKi is mediated via HCK inhibition. The gene discussed is HCK; the disease is mantle cell lymphoma.